Restructuring watch

Restructuring watch

Date Company Staff cuts Notes Current cash Cash reporting date Operating loss Op loss period
5/29/03 Allos (ALTH) 34% to61 Suspended development of BGP-15, a chemoprotectant in preclinical development. Expects to reduce its quarterly cash burn to $6-$7 million. $49.1

Read the full 422 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE